Table 1.
Demographic and clinical characteristics of the study populations at baseline.
| 4–7 years (n = 25) | 8–12 years (n = 21) | Adolescents (n = 18) | Adults (n = 129) | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean (SD) | 4.8 (0.9) | 9.4 (1.4) | 14.4 (1.2) | 30.1 (11.2) |
| Region*, n (%) | ||||
| North America | 5 (20.0%) | 4 (19.0%) | 1 (5.6%) | 28 (21.7%) |
| South America | 6 (24.0%) | 0 (0.0%) | 6 (33.3%) | 8 (6.2%) |
| Asia | 11 (44.0% | 8 (38.1%) | 4 (22.2%) | 41 (31.8%) |
| Europe | 3 (12.0%) | 9 (42.9%) | 7 (38.9%) | 52 (40.3%) |
| BMI, kg/m2 | ||||
| Mean (SD) | 15.5 (1.3) | 18.6 (3.5) | 19.7 (4.0) | 24.9 (4.6) |
| Time since diagnosis of haemophilia A, years | ||||
| Mean (SD) | 4.5 (1.4) | 8.8 (1.5) | 12.9 (3.1) | 28.6 (10.6) |
| Min–Max | 1.0–7.0 | 6.0–12.0 | 5.0–17.0 | 8.0–59.0 |
| Type of management in the 12 months preceding the trial, n (%) | ||||
| Prophylaxis | 17 (68.0%) | 14 (66.7%) | 4 (22.2%) | 46 (35.7%) |
| On-demand | 8 (32.0%) | 5 (23.8%) | 8 (44.4%) | 49 (38.7%) |
| Mixed regimen | 0 | 2 (9.5%) | 6 (33.3%) | 33 (25.6%) |
| Missing | 0 | 0 | 0 | 1 (0.8%) |
*
South America (Brazil); North America (USA); Asia (Israel, Japan, Malaysia, Russian Federation, Taiwan, Turkey); Europe (Croatia, Germany, Italy, Poland, Serbia, Spain, Switzerland, UK).